Syringe and ampoule in front of Sputnik V logoBRUSSELS, Feb 3The European Medicines Agency EMA, after a series of inspection trips within the framework of examinations of the Russian and Chinese vaccines Sputnik V and Sinovac, continues the examination process, analyzes the information, and is waiting for answers to a number of questions. Five vaccines against COVID-19 — Pfizer/BioNtech, Moderna, AstraZeneca, Johnson & Johnson and Nuvaxovid by Novavax. Four more vaccines are undergoing a gradual examination procedure: the Russian Sputnik V, the Chinese Sinovac, the French Sanofi Pasteur and the French Valneva. The German company CureVac previously withdrew an application from the EMA for the examination of its anti-coronavirus vaccine.»Sputnik V». All about the first Russian coronavirus vaccine»We continue the process of evaluating the information and data provided by the developers. As you know, we have carried out a number of inspections, we need to combine all the information, and we also need answers to a number of questions in order to continue evaluating the drugs,» EMA spokesman said at a press conference in Amsterdam. Sputnik V has been approved in 71 countries with a total population of 4 billion people, which is more than 50% of the world's population. In terms of the number of approvals received by state regulators, Sputnik V ranks second in the world. The effectiveness of the vaccine was 97.6% based on an analysis of data from 3.8 million vaccinated Russians, which is higher than the data published earlier by the medical journal The Lancet (91.6%), reported by the Russian Direct Investment Fund (RDIF) and Gamaleya Research Center. Data on the use of Sputnik V during vaccination of the population in a number of countries (Argentina, San Marino, Serbia, Hungary, Bahrain, Mexico, the United Arab Emirates and others) demonstrate that Sputnik V is one of the safest and most effective vaccines against coronavirus , RDIF reported.
